PL3472317T3 - Kompozycje i sposoby zmniejszania neowaskularyzacji oka - Google Patents

Kompozycje i sposoby zmniejszania neowaskularyzacji oka

Info

Publication number
PL3472317T3
PL3472317T3 PL17814228.7T PL17814228T PL3472317T3 PL 3472317 T3 PL3472317 T3 PL 3472317T3 PL 17814228 T PL17814228 T PL 17814228T PL 3472317 T3 PL3472317 T3 PL 3472317T3
Authority
PL
Poland
Prior art keywords
compositions
methods
ocular neovascularization
reducing ocular
reducing
Prior art date
Application number
PL17814228.7T
Other languages
English (en)
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies, Inc. filed Critical Adverum Biotechnologies, Inc.
Publication of PL3472317T3 publication Critical patent/PL3472317T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17814228.7T 2016-06-16 2017-06-16 Kompozycje i sposoby zmniejszania neowaskularyzacji oka PL3472317T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351231P 2016-06-16 2016-06-16
PCT/US2017/038012 WO2017218981A2 (en) 2016-06-16 2017-06-16 Compositions and methods for reducing ocular neovascularization

Publications (1)

Publication Number Publication Date
PL3472317T3 true PL3472317T3 (pl) 2022-08-08

Family

ID=60664289

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17814228.7T PL3472317T3 (pl) 2016-06-16 2017-06-16 Kompozycje i sposoby zmniejszania neowaskularyzacji oka

Country Status (19)

Country Link
US (2) US20190100582A1 (pl)
EP (4) EP4427808B1 (pl)
JP (4) JP6990667B2 (pl)
KR (2) KR102622823B1 (pl)
AU (2) AU2017286680B2 (pl)
CA (1) CA3027740A1 (pl)
CY (1) CY1125152T1 (pl)
DK (1) DK3472317T3 (pl)
ES (2) ES2916344T3 (pl)
HR (1) HRP20220612T1 (pl)
HU (1) HUE059424T2 (pl)
LT (1) LT3472317T (pl)
PL (1) PL3472317T3 (pl)
PT (1) PT3472317T (pl)
RS (1) RS63282B1 (pl)
SG (1) SG11201811230RA (pl)
SI (1) SI3472317T1 (pl)
SM (1) SMT202200251T1 (pl)
WO (1) WO2017218981A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
PL3472317T3 (pl) * 2016-06-16 2022-08-08 Adverum Biotechnologies, Inc. Kompozycje i sposoby zmniejszania neowaskularyzacji oka
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
KR102616820B1 (ko) 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
US20220195462A1 (en) * 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021046245A1 (en) * 2019-09-04 2021-03-11 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
JP7893739B2 (ja) * 2019-09-11 2026-07-23 アドヴェラム バイオテクノロジーズ, インコーポレイテッド アフリベルセプトをコードするaav2バリアントを使用する眼内血管新生疾患を処置する方法
WO2021071835A1 (en) * 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115335529B (zh) * 2019-11-26 2026-07-03 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
US20230149428A1 (en) * 2020-02-14 2023-05-18 Asklepios Biopharmaceutical, Inc. Method of treating gene therapy associated toxicity with antibiotics
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2022108271A (ja) * 2021-01-12 2022-07-25 Jcrファーマ株式会社 リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN115869425B (zh) * 2022-12-12 2024-08-20 北京生物制品研究所有限责任公司 一种aav眼用注射液及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
EP2346532B1 (en) * 2008-10-07 2020-10-07 Bracco Suisse SA Targeting construct comprising anti-polymer antibody and microvesicles binding to the same
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
PL3472317T3 (pl) * 2016-06-16 2022-08-08 Adverum Biotechnologies, Inc. Kompozycje i sposoby zmniejszania neowaskularyzacji oka
WO2018134168A1 (en) * 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors
JP2021197648A (ja) * 2020-06-16 2021-12-27 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、撮像装置、および、固体撮像素子の制御方法
JP7743369B2 (ja) * 2022-05-26 2025-09-24 日本キヤリア株式会社 電力変換装置

Also Published As

Publication number Publication date
SMT202200251T1 (it) 2022-07-21
JP2019521989A (ja) 2019-08-08
JP7384447B2 (ja) 2023-11-21
SI3472317T1 (sl) 2022-08-31
AU2023202277A1 (en) 2023-05-11
EP4083203A1 (en) 2022-11-02
HUE059424T2 (hu) 2022-11-28
JP2022028928A (ja) 2022-02-16
EP3472317A4 (en) 2020-02-26
DK3472317T3 (da) 2022-05-23
EP4427808B1 (en) 2026-05-20
US20230322911A1 (en) 2023-10-12
CA3027740A1 (en) 2017-12-21
EP4083203C0 (en) 2024-08-07
AU2023202277B2 (en) 2026-05-07
EP4427808A3 (en) 2024-10-30
WO2017218981A3 (en) 2018-02-15
ES2916344T3 (es) 2022-06-30
KR20190038536A (ko) 2019-04-08
RS63282B1 (sr) 2022-06-30
PT3472317T (pt) 2022-06-27
JP6990667B2 (ja) 2022-02-03
EP4083203B1 (en) 2024-08-07
WO2017218981A2 (en) 2017-12-21
EP3472317A2 (en) 2019-04-24
KR20220162881A (ko) 2022-12-08
SG11201811230RA (en) 2019-01-30
JP7606245B2 (ja) 2024-12-25
US20190100582A1 (en) 2019-04-04
JP2025038012A (ja) 2025-03-18
AU2017286680A1 (en) 2019-01-31
EP3472317B1 (en) 2022-03-16
JP2023171953A (ja) 2023-12-05
EP4674483A2 (en) 2026-01-07
LT3472317T (lt) 2022-06-27
ES2987337T3 (es) 2024-11-14
CY1125152T1 (el) 2024-12-13
HRP20220612T1 (hr) 2022-07-22
EP4427808A2 (en) 2024-09-11
AU2017286680B2 (en) 2023-01-19
KR102622823B1 (ko) 2024-01-10
EP4674483A3 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
PT3472317T (pt) Composições e métodos para reduzir a neovascularização ocular
SG10202109655VA (en) Compositions and methods for immunooncology
IL246791A0 (en) Compositions and methods for treating eye diseases
IL260124A (en) Compounds and methods for reducing tau expression
PT3426226T (pt) Composição oftalmológica
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
GB201807325D0 (en) Compositions and methods
EP3094284A4 (en) Compositions and methods for the treatment of intraocular neovascularization and/or leakage
HUE049518T2 (hu) Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
PL3373973T3 (pl) Kompozycje do oczu
IL274524A (en) Preparations and methods for aquaculture
GB201619525D0 (en) Ophthalmic composition
EP3089748A4 (en) Treating ocular neovascularization
GB201707462D0 (en) Ocular compositions
SG11201707117SA (en) Ophthalmic composition
IL249226A0 (en) Methods and preparations for immune modulation
ZA202004533B (en) Skin-brightening compositions and methods
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
PT3519050T (pt) Composições para o tratamento de condições oftálmicas
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
IL251590A0 (en) Ophthalmic preparations